Vivos Therapeutics Raises $4.64 Million Through Warrant Exercise

Vivos Therapeutics has announced the exercise of warrants for $4.64 million gross proceeds, with H.C. Wainwright & Co. as the exclusive placement agent. The company will issue new unregistered warrants to purchase up to 3,964,712 shares of common stock at an exercise price of $2.09 per share. The net proceeds will be used for working capital and general corporate purposes. The offering is expected to close on January 20, 2026, subject to customary closing conditions.